Segall Bryant & Hamill LLC Lowers Position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Segall Bryant & Hamill LLC cut its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 28.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 368,787 shares of the biotechnology company's stock after selling 148,090 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.27% of Aurinia Pharmaceuticals worth $2,965,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in AUPH. Tang Capital Management LLC raised its holdings in Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock worth $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $9,662,000. Point72 Asset Management L.P. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at about $7,630,000. Lazard Asset Management LLC increased its holdings in Aurinia Pharmaceuticals by 341.9% in the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock worth $5,355,000 after buying an additional 461,430 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Aurinia Pharmaceuticals by 84.4% in the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company's stock worth $8,327,000 after buying an additional 424,482 shares during the period. 36.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Trading Down 4.9%

AUPH opened at $8.63 on Friday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 30.82 and a beta of 1.16. Aurinia Pharmaceuticals Inc has a 52 week low of $5.20 and a 52 week high of $10.67. The business's 50 day moving average is $8.14 and its two-hundred day moving average is $8.08. The company has a quick ratio of 5.26, a current ratio of 5.93 and a debt-to-equity ratio of 0.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. On average, research analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.